RNACCartesian Therapeutics Inc. Common Stock

10.04USD-4.29%Mkt Cap: 303.76M $P/E:

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimer…